Rapamycin is used in medicine as an immunosuppressave agent (Sirolimus; RapamuneTM) although discovered as an antifungal agent. It is thought not to have antibacterial activity. Surprisingly, we found that rapamycin inhibits the germination of Bacillus brevis Nagano spores, but is inactive against Bacillus brevis Nagano vegetative cells. Surprisingly rapamycin did not show antimicrobial activity against other Bacillus strains, including other gramicidin S-producing Bacillus brevis strains such as ATCC 9999 and BI-7, whether tested as spores or vegetative cells.
Rapamycin, a nitrogen-containing triene macrolide with a very large (31-membered) lactone ring1,2), was first isolated from soil samples collected on Easter Island3). Rapamycin was originally discovered to be an antifungal antibiotic produced by Streptomyces hygroscopicus which did not show antimicrobial activity against any Gramnegative or Gram-positive bacteria tested3,4). Subsequent studies of rapamycin for clinical use demonstrated its antitumor and immunosuppressant activities5-8).
Rapamycin, structurally similar to another immunosuppressant FK506 (Tacrolimus), binds to the FK506-binding protein 12 (FKBP 12) encoded by the fprl gene. The complex inactivates protein FRAP which is a phosphatidylinositol kinase, and then inhibits T cell activation and also growth of filamentous fungi and yeast9,10) However, since rapamycin showed no activity against bacteria, bacterial species are considered to lack FKBP 12 and/or FRAP.
We have previously described the antifungal activities of rapamycin11,12). The present work reports a surprising activity that the compound exhibits against spore germination of a single strain of Bacillus brevis. LB plus 1% glucose medium and the culture tubes shaker. Growth was measured both by Klett units using a
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Klett Colorimeter (Bel-Art Products, Pequannock, NJ) and with a spectrophotometer (Shimadzu, Kyoto) at 660nm wavelength after cultivation for 16 hours.
Results
Antimicrobial Activity of Rapamycin against Bacteria
Gram-positive and Gram-negative bacteria, yeast, and a filamentous fungus were initially studied with the agardiffusion assay. As shown in Table 1 , rapamycin surprisingly inhibited the germination of spores of B. brevis Nagano strain whereas growth of vegetative cells of the other bacteria was not affected by rapamycin. As expected, growth of the yeasts C. albicans and S. cerevisiae, and the filamentous fungus, A. niger, was inhibited by rapamycin (Table 1 ).
Further Examination of Bacillus Species
Since we had found activity of rapamycin against growth from a spore suspension of B. brevis Nagano, we further tested its activity against spores and vegetative cells of other Bacillus species. Table 2 shows the results of agardiffusion assays of rapamycin against growth inoculated from spore and vegetative cell suspensions of various Bacillus species. Surprisingly, growth from vegetative cell suspensions of B. brevis Nagano was not inhibited although growth from spores was inhibited. Furthermore, rapamycin failed to inhibit growth from spores of other B. brevis strains such as ATCC 9999 and BI-7. It should be noted that B. brevis ATCC 9999 is a gramicidin S producer, just as B. brevis Nagano. Mutant B, brevis BI-7 was derived from B. brevis Nagano by N-methyl-Nnitro-Nnitrosoguanidine (NTG) treatment, lacks D-phenylalanine activating and/or racemizing enzyme, and is a nonproducing mutant13, 14) .
The activity of rapamycin against growth from spores of B. brevis Nagano was next tested by liquid assay (Table 3) . In liquid assay, three different concentrations of rapamycin were used and methanol was also tested as a control since rapamycin is dissolved in methanol. 100% methanol did not higher concentrations of rapamycin were active against growth from the spore suspension of B, brevis Nagano. Table 1 . Antimicrobial activity of rapamycin (10mg/ml) against different microorganisms as measured by agar-diffusion assay.
a Non-sporulating mutant.
b Growth was not inhibited by rapamycin; the disc diameter is 6.3mm. and in all but one case, found that rapamycin indeed does not inhibit growth of bacteria. The one exceptional case is the growth of B. brevis Nagano when inoculated with spore suspensions. Vegetative growth of B. brevis Nagano was not inhibited and neither was growth from vegetative cells or spores of two other B, brevis strains, one a gramicidin Sproducer (ATCC 9999) and the other a non-producing mutant of B. brevis Nagano (BI-7). This extreme specificity of rapamycin action is unexplained at the present time. We expect that this intriguing inhibition effect will teach us more about unknown mechanisms of rapamycin action. One might propose the existence of a protein interacting with rapamycin in B, brevis Nagano spores which is lost during germination but why would it be missing in spores of the non-producing mutant? If one postulates that it is required for gramicidin S production, why would it be absent in the Russian strain ATCC 999915-17) and present in the Japanese Nagano strain?
